Last reviewed · How we verify
New technology Enlituo — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
New technology Enlituo (New technology Enlituo) — Taizhou Mabtech Pharmaceutical Co.,Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| New technology Enlituo TARGET | New technology Enlituo | Taizhou Mabtech Pharmaceutical Co.,Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- New technology Enlituo CI watch — RSS
- New technology Enlituo CI watch — Atom
- New technology Enlituo CI watch — JSON
- New technology Enlituo alone — RSS
Cite this brief
Drug Landscape (2026). New technology Enlituo — Competitive Intelligence Brief. https://druglandscape.com/ci/new-technology-enlituo. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing